Company intelligence / Profile preview

Allos Therapeutics

Westminster, Colorado, United Statesallos.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Allos Therapeutics developed and commercialized FOLOTYN® (pralatrexate), a folate analogue metabolic inhibitor approved for the treatment of relapsed or refractory PTCL. The company was acquired by Spectrum Pharmaceuticals in September 2012. At the time of acquisition, FOLOTYN had approximately $50 million in net sales in 2011 and was being positioned for further regulatory approvals and label expansions.

Therapeutic areas: Oncology
Modalities: Small molecules (notably folate analogue metabolic inhibitors)
Industry: Biotech

Drug pipeline

1 asset

arbaclofen

Phase 3

Indications: Autism Spectrum Disorder, Fragile X Syndrome, 16p11.2 deletion syndrome

Partnerships

No major external partnerships reported; primary relationship with acquirer Spectrum Pharmaceuticals.

Beyond the preview

Go deeper on Allos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allos Therapeutics.